Answers are grounded in this paper and cite their sources.
The World Health Organization (WHO) has classified Carbapenem-resistant Acinetobacter baumannii (CRAB) as a critical-priority pathogen that requires novel antibiotics and strategies, due to its high antibiotic resistance. To combat the critical public health threat posed by CRAB, bioinformatics and immunoinformatic tools were used in this study to predict potential linear B lymphocyte (LBL), helper T lymphocyte (HTL), and cytotoxic T lymphocyte (CTL) epitopes derived from the Acinetobacter baumannii ( A. baumannii ) outer membrane proteins AdeK, PirA, and outer membrane protein 22 (Omp22). Subsequently, four combined multi-epitope vaccines (MEVs) designated ABV1-ABV4 were constructed by linking selected LBL, HTL, and CTL epitopes and Pan-HLA-DR reactive epitopes (PADRE) via GGGS and AAY linkers and fusing four different adjuvants to the N-terminus of the constructs with EAAAK linkers to increase immunogenicity. Afterward, the allergenicity, antigenicity, and solubility of ABV1-ABV4 were analyzed. The two non-allergenic candidates ABV3 and ABV4 were further analyzed for physicochemical properties and immune simulation using ExPASy ProtParam and C-ImmSim. ABV4 exhibited superior antigenicity and solubility compared with ABV3, and both ABV4 and ABV3 were predicted to induce similar immune responses; therefore, ABV4 was selected for further structural characterization and subsequent expression. The 3D structure was modeled using AlphaFold 3.0 and refined with GalaxyRefine servers. After refinement, the quality of the 3D structure improved markedly, with 97.2% of the residues in the most favored regions of the Ramachandran plot and an overall Z score of −6.11. Docking scores were −274.02 kcal/mol for ABV4–TLR2 and −302.54 kcal/mol for ABV4–TLR4. MM/PBSA calculations yielded binding free energies of −53.66 kcal/mol for ABV4–TLR2 and −68.93 kcal/mol for ABV4–TLR4. The optimized ABV4 gene was synthesized, cloned and inserted into pET28a, and expressed in E. coli BL21 with a C-terminal 6 × His tag. Immunization of mice with ABV4 induced high titers of anti-ABV4 antibodies and elevated serum IFN-γ and IL-4 levels, suggesting that ABV4 may elicit both humoral and cellular immune responses in mice. Immunofluorescence assay (IFA) and enzyme-linked immunosorbent assay (ELISA) revealed that the ABV4 antibody specifically recognized CRAB extracellular proteins without cross-reactivity to E. coli , K. pneumoniae , or P. aeruginosa, confirming that ABV4 is a promising MEV vaccine candidate against CRAB with the potential to induce humoral and cellular immune responses. Overall, ABV4 is a promising vaccine candidate against CRAB, and further experimental research is required to validate the protective efficacy in mice and elucidate the underlying mechanisms.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: